Entry
Name
Pathways in cancer - Homo sapiens (human)
Class
Human Diseases; Cancer: overview
BRITE hierarchy
Pathway map
Ortholog table
Drug
D00094 Tretinoin (JAN/USP/INN)
D00327 Fluoxymesterone (JAN/USP/INN)
D00408 Methyltestosterone (JP18/USP/INN)
D00554 Ethinyl estradiol (USP)
D00586 Flutamide (JP18/USP/INN)
D00745 Interferon alfa-2a (USAN/INN)
D00747 Interferon gamma-1b (USAN/INN)
D00753 Sirolimus (JAN/USAN/INN)
D00958 Testosterone enanthate (JP18/USP)
D00961 Bicalutamide (JP18/USP/INN)
D00966 Tamoxifen citrate (JP18/USP)
D00967 Toremifene citrate (JAN/USAN)
D01161 Fulvestrant (JAN/USP/INN)
D01441 Imatinib mesylate (USAN)
D01534 Dromostanolone propionate (USAN)
D01977 Gefitinib (JP18/USAN/INN)
D02106 Arsenic trioxide (JP18/USAN)
D02714 Everolimus (JAN/USAN/INN)
D02745 Interferon alfa-2b (USAN)
D02748 Peginterferon alfa-2b (USAN/INN)
D02970 Aprinocarsen sodium (USAN)
D03106 Bexarotene (JAN/USAN/INN)
D03305 Interferon alfa (NAMALWA) (JP18)
D03350 Canertinib dihydrochloride (USAN)
D03357 Interferon gamma-1a (genetical recombination) (JAN)
D03682 Denileukin diftitox (USAN/INN)
D04014 Enzastaurin hydrochloride (JAN/USAN)
D04023 Erlotinib hydrochloride (JAN/USAN)
D04024 Lapatinib ditosylate (USAN)
D04696 Lestaurtinib (USAN/INN)
D05029 Midostaurin (JAN/USAN/INN)
D05380 Pazopanib hydrochloride (JAN/USAN)
D05386 Pegaptanib sodium (JAN/USAN)
D06068 Temsirolimus (JAN/USAN/INN)
D06272 Sorafenib tosylate (USAN)
D06402 Sunitinib malate (JAN/USAN)
D06407 Vandetanib (JAN/USAN/INN)
D06413 Nilotinib hydrochloride hydrate (JAN)
D06554 Alvespimycin hydrochloride (USAN)
D06563 Belagenpumatucel-L (USAN)
D06637 Romidepsin (JAN/USAN/INN)
D06889 Pegfilgrastim (USAN/INN)
D07434 Polyestradiol phosphate (INN)
D07741 Zibotentan (JAN/USAN/INN)
D08805 Interferon gamma-n1 (JAN)
D08883 Cediranib maleate (JAN/USAN)
D08900 Ridaforolimus (JAN/USAN/INN)
D08917 Ezatiostat hydrochloride (USAN)
D08947 Motesanib diphosphate (USAN)
D08956 Omacetaxine mepesuccinate (USAN)
D08971 Plerixafor (JAN/USAN/INN)
D09338 Entinostat (JAN/USAN/INN)
D09357 Mocetinostat dihydrobromide (USAN)
D09630 Imetelstat sodium (USAN)
D09641 Mocetinostat (USAN/INN)
D09690 Varlitinib tosylate (USAN)
D09728 Bosutinib hydrate (JAN)
D09731 Crizotinib (JAN/USAN/INN)
D09733 Afatinib dimaleate (USAN)
D09865 Amuvatinib hydrochloride (USAN)
D09910 Gataparsen sodium (USAN)
D09920 Lenvatinib mesylate (USAN)
D09951 Ponatinib hydrochloride (JAN/USAN)
D09956 Quizartinib dihydrochloride (USAN)
D09960 Ruxolitinib phosphate (JAN/USAN)
D09980 Trastuzumab emtansine (USAN/INN)
D09996 Vemurafenib (JAN/USAN/INN)
D10015 Litgenprostucel-L (USAN)
D10019 Panobinostat lactate (JAN)
D10084 Abexinostat hydrochloride (USAN)
D10095 Cabozantinib s-malate (USAN)
D10103 Crenolanib besylate (USAN)
D10104 Dabrafenib mesylate (USAN)
D10137 Regorafenib hydrate (JAN)
D10164 Sepantronium bromide (JAN/USAN)
D10173 Tivantinib (JAN/USAN/INN)
D10176 Trametinib dimethyl sulfoxide (JAN/USAN)
D10190 Tivozanib hydrochloride (USAN)
D10218 Enzalutamide (JAN/USAN)
D10319 Panobinostat (USAN/INN)
D10322 Quisinostat hydrochloride (USAN)
D10325 Patidegib hydrochloride (USAN)
D10382 Afuresertib hydrochloride (USAN)
D10396 Nintedanib esylate (USAN)
D10399 Rebastinib Tosylate (USAN)
D10437 Galunisertib (USAN/INN)
D10446 Margetuximab (USAN/INN)
D10450 Alectinib hydrochloride (JAN)
D10464 Firtecan pegol (USAN/INN)
D10465 Golvatinib tartrate (USAN)
D10486 Pimasertib hydrochloride (USAN)
D10551 Ceritinib (JAN/USAN/INN)
D10560 Idelalisib (JAN/USAN/INN)
D10604 Binimetinib (JAN/USAN/INN)
D10609 Buparlisib hydrochloride (JAN/USAN)
D10615 Cobimetinib fumarate (USAN)
D10616 Dactolisib tosylate (USAN)
D10652 Palbociclib isethionate (USAN)
D10679 Venetoclax (JAN/USAN/INN)
D10688 Abemaciclib (JAN/USAN/INN)
D10709 Gilteritinib (USAN/INN)
D10717 Napabucasin (JAN/USAN/INN)
D10729 Sonidegib phosphate (USAN)
D10766 Osimertinib mesylate (USAN)
D10797 Copanlisib hydrochloride (USAN)
D10798 Copanlisib hydrochloride hydrate (JAN)
D10800 Gilteritinib fumarate (JAN/USAN)
D10891 Capmatinib hydrochloride (USAN)
D10926 Entrectinib (JAN/USAN/INN)
D10927 Erdafitinib (JAN/USAN/INN)
D10977 Remetinostat (USAN/INN)
D10979 Ribociclib succinate (USAN)
D10981 Rovalpituzumab tesirine (USAN/INN)
D10993 Tucidinostat (JAN/USAN/INN)
D11011 Alpelisib (JAN/USAN/INN)
D11012 Lorlatinib (JAN/USAN/INN)
D11045 Darolutamide (JAN/USAN/INN)
D11053 Encorafenib (JAN/USAN/INN)
D11073 Tepotinib hydrochloride (USAN)
D11074 Ipatasertib hydrochloride (JAN)
D11107 Glasdegib maleate (JAN)
D11115 Olmutinib hydrochloride (USAN)
D11126 Navicixizumab (USAN/INN)
D11137 Larotrectinib (USAN/INN)
D11138 Larotrectinib sulfate (JAN/USAN)
D11139 Savolitinib (JAN/USAN/INN)
D11140 Sitravatinib (USAN/INN)
D11151 Crenigacestat (USAN/INN)
D11182 Tinostamustine (USAN/INN)
D11185 Ralaniten acetate (USAN)
D11229 Brontictuzumab (USAN/INN)
D11264 Brilanestrant (USAN/INN)
D11270 Pexidartinib (USAN/INN)
D11271 Pexidartinib hydrochloride (JAN/USAN)
D11285 Ravoxertinib (USAN/INN)
D11323 Umbralisib tosylate (USAN)
D11344 Telisotuzumab vedotin (USAN)
D11356 Ensartinib hydrochloride (USAN)
D11371 Capivasertib (JAN/USAN)
D11404 Asciminib hydrochloride (JAN/USAN)
D11411 Lifirafenib maleate (USAN)
D11417 Pemigatinib (JAN/USAN/INN)
D11434 Nazartinib mesylate (USAN)
D11454 Repotrectinib (JAN/USAN)
D11461 Derazantinib hydrochloride (USAN)
D11506 Parsaclisib hydrochloride (JAN/USAN)
D11508 Miransertib mesylate (USAN)
D11529 Trastuzumab deruxtecan (USAN/INN)
D11541 Sitravatinib malate (USAN)
D11589 Infigratinib (USAN/INN)
D11600 Zotiraciclib citrate (USAN)
D11658 Duvelisib hydrate (JAN)
D11669 Bempegaldesleukin (USAN/INN)
D11672 Elacestrant hydrochloride (USAN)
D11713 Selpercatinib (JAN/USAN/INN)
D11725 Futibatinib (JAN/USAN/INN)
D11773 Tesevatinib tosylate (USAN)
D11803 Cetuximab sarotalocan (USAN/INN)
D11805 Cetuximab sarotalocan sodium (genetical recombination) (JAN)
D11821 Nogapendekin alfa (USAN/INN)
D11874 Serclutamab talirine (USAN/INN)
D11954 Belzutifan (JAN/USAN/INN)
D11961 Giredestrant (USAN/INN)
D11969 Mobocertinib succinate (JAN)
D11987 Trilaciclib dihydrochloride
D12001 Mobocertinib (USAN/INN)
D12009 Zandelisib (JAN/USAN/INN)
D12049 Camizestrant (JAN/USAN)
D12060 Temuterkib mesylate (USAN)
D12128 Balixafortide (USAN/INN)
D12145 Amcenestrant (JAN/USAN/INN)
D12175 Olverembatinib (USAN/INN)
D12230 Poziotinib hydrochloride (USAN)
D12245 Lazertinib mesylate (USAN)
D12258 Aumolertinib (USAN/INN)
D12259 Aumolertinib mesylate (USAN)
D12281 Motixafortide (USAN/INN)
D12282 Motixafortide acetate (USAN)
D12303 Deutenzalutamide (USAN)
D12331 Zeteletinib adipate (USAN)
D12354 Pralsetinib hydrate (JAN)
D12363 Taletrectinib (USAN/INN)
D12364 Taletrectinib adipate (JAN/USAN)
D12399 Sulanemadlin (USAN/INN)
D12405 Tasurgratinib succinate (JAN)
D12416 Petosemtamab (USAN/INN)
D12442 Tucatinib ethanolate (JAN)
D12444 Nilotinib hydrochloride dihydrate (JAN)
D12457 Tuxobertinib (USAN/INN)
D12506 Sunvozertinib (USAN/INN)
D12515 Avutometinib (USAN/INN)
D12526 Catequentinib (USAN/INN)
D12531 Nadofaragene firadenovec (USAN/INN)
D12534 Avutometinib potassium (USAN)
D12537 Catequentinib hydrochloride (USAN)
D12545 Tinengotinib (USAN/INN)
D12552 Bocodepsin besylate (USAN)
D12557 Elzovantinib (USAN/INN)
D12583 Anvatabart opadotin (USAN/INN)
D12584 Anvatabart pactil (USAN/INN)
D12600 Bezuclastinib (USAN/INN)
D12625 Pegenzileukin (USAN/INN)
D12628 Vepdegestrant (JAN/USAN/INN)
D12640 Divarasib adipate (USAN)
D12641 Emirodatamab (USAN/INN)
D12646 Paltimatrectinib (USAN/INN)
D12650 Zanzalintinib (USAN/INN)
D12651 Zanzalintinib fumarate (USAN)
D12705 Gumarontinib hydrate (JAN)
D12809 Bafisontamab (USAN/INN)
D12827 Palazestrant (USAN/INN)
D12837 Risovalisib mesilate hydrate (JAN)
D12854 Nilotinib laurylsulfate (USAN)
D12879 Zongertinib (JAN/USAN/INN)
D12888 Nogapendekin alfa inbakicept
D12922 Tizaterkib adipate (USAN)
D12925 Pocenbrodib hydrochloride (USAN)
D12943 Giredestrant tartrate (JAN)
D12956 Firmonertinib (USAN/INN)
D12957 Firmonertinib mesylate (USAN)
D13008 Nilotinib tartaric acid (USAN)
Organism
Homo sapiens (human) [GN:
hsa ]
Gene
26060 APPL1; adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 [KO:K08733 ]
10297 APC2; APC regulator of WNT signaling pathway 2 [KO:K02085 ]
324 APC; APC regulator of WNT signaling pathway [KO:K02085 ]
83439 TCF7L1; transcription factor 7 like 1 [KO:K04490 ]
6934 TCF7L2; transcription factor 7 like 2 [KO:K04491 ]
51176 LEF1; lymphoid enhancer binding factor 1 [KO:K04492 ]
332 BIRC5; baculoviral IAP repeat containing 5 [KO:K08731 ]
4609 MYC; MYC proto-oncogene, bHLH transcription factor [KO:K04377 ]
4040 LRP6; LDL receptor related protein 6 [KO:K03068 ]
4041 LRP5; LDL receptor related protein 5 [KO:K03068 ]
1855 DVL1; dishevelled segment polarity protein 1 [KO:K02353 ]
1856 DVL2; dishevelled segment polarity protein 2 [KO:K02353 ]
1857 DVL3; dishevelled segment polarity protein 3 [KO:K02353 ]
10023 FRAT1; FRAT regulator of WNT signaling pathway 1 [KO:K03069 ]
23401 FRAT2; FRAT regulator of WNT signaling pathway 2 [KO:K03096 ]
2149 F2R; coagulation factor II thrombin receptor [KO:K03914 ]
9002 F2RL3; F2R like thrombin or trypsin receptor 3 [KO:K04236 ]
1902 LPAR1; lysophosphatidic acid receptor 1 [KO:K04289 ]
9170 LPAR2; lysophosphatidic acid receptor 2 [KO:K04291 ]
23566 LPAR3; lysophosphatidic acid receptor 3 [KO:K04294 ]
2846 LPAR4; lysophosphatidic acid receptor 4 [KO:K04275 ]
57121 LPAR5; lysophosphatidic acid receptor 5 [KO:K08390 ]
10161 LPAR6; lysophosphatidic acid receptor 6 [KO:K04273 ]
185 AGTR1; angiotensin II receptor type 1 [KO:K04166 ]
2768 GNA12; G protein subunit alpha 12 [KO:K04346 ]
23365 ARHGEF12; Rho guanine nucleotide exchange factor 12 [KO:K07532 ]
9826 ARHGEF11; Rho guanine nucleotide exchange factor 11 [KO:K12331 ]
9138 ARHGEF1; Rho guanine nucleotide exchange factor 1 [KO:K12330 ]
57449 PLEKHG5; pleckstrin homology and RhoGEF domain containing G5 [KO:K19464 ]
387 RHOA; ras homolog family member A [KO:K04513 ]
6387 CXCL12; C-X-C motif chemokine ligand 12 [KO:K10031 ]
7852 CXCR4; C-X-C motif chemokine receptor 4 [KO:K04189 ]
2770 GNAI1; G protein subunit alpha i1 [KO:K04630 ]
2771 GNAI2; G protein subunit alpha i2 [KO:K04630 ]
2773 GNAI3; G protein subunit alpha i3 [KO:K04630 ]
5731 PTGER1; prostaglandin E receptor 1 [KO:K04258 ]
5732 PTGER2; prostaglandin E receptor 2 [KO:K04259 ]
5733 PTGER3; prostaglandin E receptor 3 [KO:K04260 ]
5734 PTGER4; prostaglandin E receptor 4 [KO:K04261 ]
2790 GNG10; G protein subunit gamma 10 [KO:K04545 ]
2791 GNG11; G protein subunit gamma 11 [KO:K04546 ]
2792 GNGT1; G protein subunit gamma transducin 1 [KO:K04548 ]
2793 GNGT2; G protein subunit gamma transducin 2 [KO:K04549 ]
1282 COL4A1; collagen type IV alpha 1 chain [KO:K06237 ]
1284 COL4A2; collagen type IV alpha 2 chain [KO:K06237 ]
1285 COL4A3; collagen type IV alpha 3 chain [KO:K06237 ]
1286 COL4A4; collagen type IV alpha 4 chain [KO:K06237 ]
1287 COL4A5; collagen type IV alpha 5 chain [KO:K06237 ]
1288 COL4A6; collagen type IV alpha 6 chain [KO:K06237 ]
3674 ITGA2B; integrin subunit alpha 2b [KO:K06476 ]
5290 PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922 ] [EC:2.7.1.153 ]
5291 PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922 ] [EC:2.7.1.153 ]
5293 PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922 ] [EC:2.7.1.153 ]
5295 PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649 ]
5296 PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649 ]
8503 PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649 ]
1147 CHUK; component of inhibitor of nuclear factor kappa B kinase complex [KO:K04467 ] [EC:2.7.11.10 ]
8517 IKBKG; inhibitor of nuclear factor kappa B kinase regulatory subunit gamma [KO:K07210 ]
4790 NFKB1; nuclear factor kappa B subunit 1 [KO:K02580 ]
4791 NFKB2; nuclear factor kappa B subunit 2 [KO:K04469 ]
5970 RELA; RELA proto-oncogene, NF-kB subunit [KO:K04735 ]
596 BCL2; BCL2 apoptosis regulator [KO:K02161 ]
329 BIRC2; baculoviral IAP repeat containing 2 [KO:K16060 ]
330 BIRC3; baculoviral IAP repeat containing 3 [KO:K16060 ]
79444 BIRC7; baculoviral IAP repeat containing 7 [KO:K16061 ]
7185 TRAF1; TNF receptor associated factor 1 [KO:K03172 ]
7187 TRAF3; TNF receptor associated factor 3 [KO:K03174 ]
9618 TRAF4; TNF receptor associated factor 4 [KO:K09848 ]
7188 TRAF5; TNF receptor associated factor 5 [KO:K09849 ]
572 BAD; BCL2 associated agonist of cell death [KO:K02158 ]
1027 CDKN1B; cyclin dependent kinase inhibitor 1B [KO:K06624 ]
1026 CDKN1A; cyclin dependent kinase inhibitor 1A [KO:K06625 ]
25 ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase [KO:K06619 ] [EC:2.7.10.2 ]
1398 CRK; CRK proto-oncogene, adaptor protein [KO:K04438 ]
1399 CRKL; CRK like proto-oncogene, adaptor protein [KO:K04438 ]
6776 STAT5A; signal transducer and activator of transcription 5A [KO:K11223 ]
6777 STAT5B; signal transducer and activator of transcription 5B [KO:K11224 ]
623 BDKRB1; bradykinin receptor B1 [KO:K03915 ]
624 BDKRB2; bradykinin receptor B2 [KO:K03916 ]
1909 EDNRA; endothelin receptor type A [KO:K04197 ]
1910 EDNRB; endothelin receptor type B [KO:K04198 ]
2767 GNA11; G protein subunit alpha 11 [KO:K04635 ]
3559 IL2RA; interleukin 2 receptor subunit alpha [KO:K05068 ]
3560 IL2RB; interleukin 2 receptor subunit beta [KO:K05069 ]
3561 IL2RG; interleukin 2 receptor subunit gamma [KO:K05070 ]
3563 IL3RA; interleukin 3 receptor subunit alpha [KO:K04737 ]
1439 CSF2RB; colony stimulating factor 2 receptor subunit beta [KO:K04738 ]
3568 IL5RA; interleukin 5 receptor subunit alpha [KO:K05067 ]
3572 IL6ST; interleukin 6 cytokine family signal transducer [KO:K05060 ]
3594 IL12RB1; interleukin 12 receptor subunit beta 1 [KO:K05063 ]
3595 IL12RB2; interleukin 12 receptor subunit beta 2 [KO:K05064 ]
3597 IL13RA1; interleukin 13 receptor subunit alpha 1 [KO:K05076 ]
3601 IL15RA; interleukin 15 receptor subunit alpha [KO:K05074 ]
3454 IFNAR1; interferon alpha and beta receptor subunit 1 [KO:K05130 ]
3455 IFNAR2; interferon alpha and beta receptor subunit 2 [KO:K05131 ]
3459 IFNGR1; interferon gamma receptor 1 [KO:K05132 ]
3460 IFNGR2; interferon gamma receptor 2 [KO:K05133 ]
10125 RASGRP1; RAS guanyl releasing protein 1 [KO:K04350 ]
10235 RASGRP2; RAS guanyl releasing protein 2 [KO:K12361 ]
25780 RASGRP3; RAS guanyl releasing protein 3 [KO:K12362 ]
6774 STAT3; signal transducer and activator of transcription 3 [KO:K04692 ]
6772 STAT1; signal transducer and activator of transcription 1 [KO:K11220 ]
6773 STAT2; signal transducer and activator of transcription 2 [KO:K11221 ]
6775 STAT4; signal transducer and activator of transcription 4 [KO:K11222 ]
6778 STAT6; signal transducer and activator of transcription 6 [KO:K11225 ]
7422 VEGFA; vascular endothelial growth factor A [KO:K05448 ]
7423 VEGFB; vascular endothelial growth factor B [KO:K16858 ]
2277 VEGFD; vascular endothelial growth factor D [KO:K05449 ]
7424 VEGFC; vascular endothelial growth factor C [KO:K05449 ]
7039 TGFA; transforming growth factor alpha [KO:K08774 ]
5154 PDGFA; platelet derived growth factor subunit A [KO:K04359 ]
5155 PDGFB; platelet derived growth factor subunit B [KO:K17386 ]
3479 IGF1; insulin like growth factor 1 [KO:K05459 ]
3481 IGF2; insulin like growth factor 2 [KO:K13769 ]
2323 FLT3LG; fms related receptor tyrosine kinase 3 ligand [KO:K05454 ]
2255 FGF10; fibroblast growth factor 10 [KO:K04358 ]
8817 FGF18; fibroblast growth factor 18 [KO:K04358 ]
8822 FGF17; fibroblast growth factor 17 [KO:K04358 ]
8823 FGF16; fibroblast growth factor 16 [KO:K04358 ]
9965 FGF19; fibroblast growth factor 19 [KO:K22603 ]
8074 FGF23; fibroblast growth factor 23 [KO:K22428 ]
2885 GRB2; growth factor receptor bound protein 2 [KO:K04364 ]
6654 SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099 ]
6655 SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099 ]
3265 HRAS; HRas proto-oncogene, GTPase [KO:K02833 ]
3845 KRAS; KRAS proto-oncogene, GTPase [KO:K07827 ]
4893 NRAS; NRAS proto-oncogene, GTPase [KO:K07828 ]
3725 JUN; Jun proto-oncogene, AP-1 transcription factor subunit [KO:K04448 ]
2353 FOS; Fos proto-oncogene, AP-1 transcription factor subunit [KO:K04379 ]
2113 ETS1; ETS proto-oncogene 1, transcription factor [KO:K02678 ]
3576 CXCL8; C-X-C motif chemokine ligand 8 [KO:K10030 ]
8030 CCDC6; coiled-coil domain containing 6 [KO:K09288 ]
8031 NCOA4; nuclear receptor coactivator 4 [KO:K09289 ]
7175 TPR; translocated promoter region, nuclear basket protein [KO:K09291 ]
10342 TFG; trafficking from ER to golgi regulator [KO:K09292 ]
11186 RASSF1; Ras association domain family member 1 [KO:K09850 ]
83593 RASSF5; Ras association domain family member 5 [KO:K08015 ]
2002 ELK1; ETS transcription factor ELK1 [KO:K04375 ]
815 CAMK2A; calcium/calmodulin dependent protein kinase II alpha [KO:K04515 ] [EC:2.7.11.17 ]
816 CAMK2B; calcium/calmodulin dependent protein kinase II beta [KO:K04515 ] [EC:2.7.11.17 ]
817 CAMK2D; calcium/calmodulin dependent protein kinase II delta [KO:K04515 ] [EC:2.7.11.17 ]
818 CAMK2G; calcium/calmodulin dependent protein kinase II gamma [KO:K04515 ] [EC:2.7.11.17 ]
5900 RALGDS; ral guanine nucleotide dissociation stimulator [KO:K08732 ]
998 CDC42; cell division cycle 42 [KO:K04393 ]
5468 PPARG; peroxisome proliferator activated receptor gamma [KO:K08530 ]
5915 RARB; retinoic acid receptor beta [KO:K08528 ]
5467 PPARD; peroxisome proliferator activated receptor delta [KO:K04504 ]
7704 ZBTB16; zinc finger and BTB domain containing 16 [KO:K10055 ]
5914 RARA; retinoic acid receptor alpha [KO:K08527 ]
5371 PML; PML nuclear body scaffold [KO:K10054 ] [EC:2.3.2.-]
861 RUNX1; RUNX family transcription factor 1 [KO:K08367 ]
862 RUNX1T1; RUNX1 partner transcriptional co-repressor 1 [KO:K10053 ]
1050 CEBPA; CCAAT enhancer binding protein alpha [KO:K09055 ]
1438 CSF2RA; colony stimulating factor 2 receptor subunit alpha [KO:K05066 ]
1441 CSF3R; colony stimulating factor 3 receptor [KO:K05061 ]
1029 CDKN2A; cyclin dependent kinase inhibitor 2A [KO:K06621 ]
7709 ZBTB17; zinc finger and BTB domain containing 17 [KO:K10500 ]
1030 CDKN2B; cyclin dependent kinase inhibitor 2B [KO:K04685 ]
1163 CKS1B; CDC28 protein kinase regulatory subunit 1B [KO:K02219 ]
1164 CKS2; CDC28 protein kinase regulatory subunit 2 [KO:K02219 ]
6500 SKP1; S-phase kinase associated protein 1 [KO:K03094 ]
6502 SKP2; S-phase kinase associated protein 2 [KO:K03875 ]
5925 RB1; RB transcriptional corepressor 1 [KO:K06618 ]
10912 GADD45G; growth arrest and DNA damage inducible gamma [KO:K04402 ]
1647 GADD45A; growth arrest and DNA damage inducible alpha [KO:K04402 ]
4616 GADD45B; growth arrest and DNA damage inducible beta [KO:K04402 ]
581 BAX; BCL2 associated X, apoptosis regulator [KO:K02159 ]
578 BAK1; BCL2 antagonist/killer 1 [KO:K14021 ]
1643 DDB2; damage specific DNA binding protein 2 [KO:K10140 ]
4286 MITF; melanocyte inducing transcription factor [KO:K09455 ]
7040 TGFB1; transforming growth factor beta 1 [KO:K13375 ]
7042 TGFB2; transforming growth factor beta 2 [KO:K13376 ]
7043 TGFB3; transforming growth factor beta 3 [KO:K13377 ]
675 BRCA2; BRCA2 DNA repair associated [KO:K08775 ]
355 FAS; Fas cell surface death receptor [KO:K04390 ]
8772 FADD; Fas associated via death domain [KO:K02373 ]
637 BID; BH3 interacting domain death agonist [KO:K04726 ]
5366 PMAIP1; phorbol-12-myristate-13-acetate-induced protein 1 [KO:K10131 ]
317 APAF1; apoptotic peptidase activating factor 1 [KO:K02084 ]
9817 KEAP1; kelch like ECH associated protein 1 [KO:K10456 ]
4780 NFE2L2; NFE2 like bZIP transcription factor 2 [KO:K05638 ]
7428 VHL; von Hippel-Lindau tumor suppressor [KO:K03871 ]
3091 HIF1A; hypoxia inducible factor 1 subunit alpha [KO:K08268 ]
2034 EPAS1; endothelial PAS domain protein 1 [KO:K09095 ]
405 ARNT; aryl hydrocarbon receptor nuclear translocator [KO:K09097 ]
9915 ARNT2; aryl hydrocarbon receptor nuclear translocator 2 [KO:K15589 ]
6513 SLC2A1; solute carrier family 2 member 1 [KO:K07299 ]
182 JAG1; jagged canonical Notch ligand 1 [KO:K06052 ]
3714 JAG2; jagged canonical Notch ligand 2 [KO:K21635 ]
10683 DLL3; delta like canonical Notch ligand 3 [KO:K06051 ]
28514 DLL1; delta like canonical Notch ligand 1 [KO:K06051 ]
54567 DLL4; delta like canonical Notch ligand 4 [KO:K06051 ]
3280 HES1; hes family bHLH transcription factor 1 [KO:K06054 ]
388585 HES5; hes family bHLH transcription factor 5 [KO:K06055 ]
23462 HEY1; hes related family bHLH transcription factor with YRPW motif 1 [KO:K09091 ]
23493 HEY2; hes related family bHLH transcription factor with YRPW motif 2 [KO:K09091 ]
26508 HEYL; hes related family bHLH transcription factor with YRPW motif like [KO:K09091 ]
6469 SHH; sonic hedgehog signaling molecule [KO:K11988 ]
6608 SMO; smoothened, frizzled class receptor [KO:K06226 ]
51684 SUFU; SUFU negative regulator of hedgehog signaling [KO:K06229 ]
650 BMP2; bone morphogenetic protein 2 [KO:K21283 ]
652 BMP4; bone morphogenetic protein 4 [KO:K04662 ]
3320 HSP90AA1; heat shock protein 90 alpha family class A member 1 [KO:K04079 ]
3326 HSP90AB1; heat shock protein 90 alpha family class B member 1 [KO:K04079 ]
7184 HSP90B1; heat shock protein 90 beta family member 1 [KO:K09487 ]
Compound
C00681 1-Acyl-sn-glycerol 3-phosphate
C01245 D-myo-Inositol 1,4,5-trisphosphate
C05981 Phosphatidylinositol-3,4,5-trisphosphate
C16038 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
Reference
Authors
Weinberg RA.
Title
The biology of cancer
Journal
Garland Science, Taylor & Francis Group, LLC (2007)
Reference
Authors
Hanahan D, Weinberg RA
Title
The hallmarks of cancer.
Journal
Reference
Authors
Grady WM.
Title
Genomic instability and colon cancer.
Journal
Reference
Authors
Soreide K, Janssen EA, Soiland H, Korner H, Baak JP.
Title
Microsatellite instability in colorectal cancer.
Journal
Reference
Authors
Anwar S, Hall C, White J, Deakin M, Farrell W, Elder JB.
Title
Hereditary non-polyposis colorectal cancer: an updated review.
Journal
Reference
Authors
Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y.
Title
Colorectal cancer: genetics of development and metastasis.
Journal
Reference
Authors
Lynch HT, de la Chapelle A.
Title
Hereditary colorectal cancer.
Journal
Reference
Authors
Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C.
Title
The significance of unstable chromosomes in colorectal cancer.
Journal
Reference
Authors
Behrens J.
Title
Cadherins and catenins: role in signal transduction and tumor progression.
Journal
Reference
Authors
Behrens J.
Title
The role of the Wnt signalling pathway in colorectal tumorigenesis.
Journal
Reference
Authors
Behrens J, Lustig B.
Title
The Wnt connection to tumorigenesis.
Journal
Reference
Authors
Polakis P.
Title
The adenomatous polyposis coli (APC) tumor suppressor.
Journal
Reference
Authors
Janssen KP.
Title
Murine models of colorectal cancer: studying the role of oncogenic K-ras.
Journal
Reference
Authors
Adjei AA.
Title
Blocking oncogenic Ras signaling for cancer therapy.
Journal
Reference
Authors
Arakawa H.
Title
Netrin-1 and its receptors in tumorigenesis.
Journal
Reference
Authors
Mehlen P, Fearon ER.
Title
Role of the dependence receptor DCC in colorectal cancer pathogenesis.
Journal
Reference
Authors
Peltomaki P.
Title
DNA mismatch repair and cancer.
Journal
Reference
Authors
Li F, Cao Y, Townsend CM Jr, Ko TC.
Title
TGF-beta signaling in colon cancer cells.
Journal
Reference
Authors
Roman C, Saha D, Beauchamp R.
Title
TGF-beta and colorectal carcinogenesis.
Journal
Reference
Authors
Watson AJ.
Title
An overview of apoptosis and the prevention of colorectal cancer.
Journal
Reference
Authors
Watson AJ.
Title
Apoptosis and colorectal cancer.
Journal
Reference
Authors
Houlston RS.
Title
What we could do now: molecular pathology of colorectal cancer.
Journal
Reference
Authors
Von Hoff D, Evans D, Hruban R (ed).
Title
Pancreatic cancer
Journal
Jones and Bartlett publishers (2005)
Reference
Authors
Niitsu Y, Yokota J (ed).
Title
[Oncogenes and Tumor Suppressor Genes for Medical Oncologist] (In Japanese)
Journal
Nankodo (1999)
Reference
Authors
Bardeesy N, DePinho RA.
Title
Pancreatic cancer biology and genetics.
Journal
Reference
Authors
Bardeesy N, Sharpless NE, DePinho RA, Merlino G.
Title
The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model.
Journal
Reference
Authors
Cowgill SM, Muscarella P.
Title
The genetics of pancreatic cancer.
Journal
Reference
Authors
Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA.
Title
Genetics and biology of pancreatic ductal adenocarcinoma.
Journal
Reference
Authors
Shields JM, Pruitt K, McFall A, Shaub A, Der CJ.
Title
Understanding Ras: 'it ain't over 'til it's over'.
Journal
Reference
Authors
Holbro T, Civenni G, Hynes NE.
Title
The ErbB receptors and their role in cancer progression.
Journal
Reference
Authors
Marmor MD, Skaria KB, Yarden Y.
Title
Signal transduction and oncogenesis by ErbB/HER receptors.
Journal
Reference
Authors
DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, Freeman JW.
Title
Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines.
Journal
Reference
Authors
Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K.
Title
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.
Journal
Reference
Authors
Toyonaga T, Nakano K, Nagano M, Zhao G, Yamaguchi K, Kuroki S, Eguchi T, Chijiiwa K, Tsuneyoshi M, Tanaka M.
Title
Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer.
Journal
Reference
Authors
Schmid RM.
Title
Genetic basis of pancreatic cancer.
Journal
Reference
Authors
Elliott RL, Blobe GC.
Title
Role of transforming growth factor Beta in human cancer.
Journal
Reference
Authors
Rudkin TM, Foulkes WD.
Title
BRCA2: breaks, mistakes and failed separations.
Journal
Reference
Authors
Venkitaraman AR.
Title
Functions of BRCA1 and BRCA2 in the biological response to DNA damage.
Journal
J Cell Sci 114:3591-8 (2001)
Reference
Authors
Soni D, King JA, Kaye AH, Hovens CM.
Title
Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge.
Journal
Reference
Authors
Zhu Y, Parada LF.
Title
The molecular and genetic basis of neurological tumours.
Journal
Reference
Authors
Holland EC.
Title
Gliomagenesis: genetic alterations and mouse models.
Journal
Reference
Authors
Bansal K, Liang ML, Rutka JT.
Title
Molecular biology of human gliomas.
Journal
Reference
Authors
Tabuchi K (ed).
Title
[Gliomas: Research and therapy] (In Japanese)
Journal
Springer-Verlag Tokyo (2006)
Reference
Authors
Kapoor GS, O'Rourke DM.
Title
Mitogenic signaling cascades in glial tumors.
Journal
Reference
Authors
Hulleman E, Helin K.
Title
Molecular mechanisms in gliomagenesis.
Journal
Reference
Authors
Schlessinger J.
Title
Cell signaling by receptor tyrosine kinases.
Journal
Reference
Authors
Ng HK, Lam PY.
Title
The molecular genetics of central nervous system tumors.
Journal
Reference
Authors
Knobbe CB, Merlo A, Reifenberger G.
Title
Pten signaling in gliomas.
Journal
Reference
Authors
Kondo T, Ezzat S, Asa SL.
Title
Pathogenetic mechanisms in thyroid follicular-cell neoplasia.
Journal
Reference
Authors
Chiloeches A, Marais R.
Title
Is BRAF the Achilles' Heel of thyroid cancer?
Journal
Reference
Authors
Reddi HV, McIver B, Grebe SK, Eberhardt NL
Title
The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis.
Journal
Reference
Authors
Santoro M, Melillo RM, Fusco A.
Title
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.
Journal
Reference
Authors
Pierotti MA, Greco A.
Title
Oncogenic rearrangements of the NTRK1/NGF receptor.
Journal
Reference
Authors
Sobrinho-Simoes M, Preto A, Rocha AS, Castro P, Maximo V, Fonseca E, Soares P.
Title
Molecular pathology of well-differentiated thyroid carcinomas.
Journal
Reference
Authors
Gimm O.
Title
Thyroid cancer.
Journal
Reference
Authors
Williams D.
Title
Cancer after nuclear fallout: lessons from the Chernobyl accident.
Journal
Reference
Authors
Steffen B, Muller-Tidow C, Schwable J, Berdel WE, Serve H.
Title
The molecular pathogenesis of acute myeloid leukemia.
Journal
Reference
Authors
Tenen DG.
Title
Disruption of differentiation in human cancer: AML shows the way.
Journal
Reference
Authors
Choudhary C, Muller-Tidow C, Berdel WE, Serve H.
Title
Signal transduction of oncogenic Flt3.
Journal
Reference
Authors
Stirewalt DL, Radich JP.
Title
The role of FLT3 in haematopoietic malignancies.
Journal
Reference
Authors
Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L.
Title
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.
Journal
Reference
Authors
Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R.
Title
Normal and oncogenic forms of the receptor tyrosine kinase kit.
Journal
Reference
Authors
Lorsbach RB, Downing JR.
Title
The role of the AML1 transcription factor in leukemogenesis.
Journal
Reference
Authors
Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Bohmer FD, Muller-Tidow C, Berdel WE, Serve H.
Title
Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.
Journal
Reference
Authors
Mikesch JH, Steffen B, Berdel WE, Serve H, Muller-Tidow C.
Title
The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia.
Journal
Reference
Authors
Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, Buergi U, Tenen DG.
Title
ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.
Journal
Reference
Authors
Ren R.
Title
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
Journal
Reference
Authors
Deininger MW, Goldman JM, Melo JV.
Title
The molecular biology of chronic myeloid leukemia.
Journal
Blood 96:3343-56 (2000)
Reference
Authors
Calabretta B, Perrotti D.
Title
The biology of CML blast crisis.
Journal
Reference
Authors
Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM.
Title
The biology of chronic myeloid leukemia.
Journal
Reference
Authors
Mitani K.
Title
Molecular mechanisms of leukemogenesis by AML1/EVI-1.
Journal
Reference
Authors
Dong M, Blobe GC.
Title
Role of transforming growth factor-beta in hematologic malignancies.
Journal
Reference
Authors
Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H.
Title
The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
Journal
Blood 92:4003-12 (1998)
Reference
Authors
Brusa G, Benvenuti M, Mazzacurati L, Mancini M, Pattacini L, Martinelli G, Barbieri E, Greenberger JS, Baccarani M, Santucci MA.
Title
p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
Journal
Haematologica 88:622-30 (2003)
Reference
Authors
Baldwin AS.
Title
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.
Journal
Reference
Authors
Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL.
Title
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.
Journal
Reference
Authors
Tilli CM, Van Steensel MA, Krekels GA, Neumann HA, Ramaekers FC.
Title
Molecular aetiology and pathogenesis of basal cell carcinoma.
Journal
Reference
Authors
Saldanha G, Fletcher A, Slater DN.
Title
Basal cell carcinoma: a dermatopathological and molecular biological update.
Journal
Reference
Authors
Daya-Grosjean L, Couve-Privat S.
Title
Sonic hedgehog signaling in basal cell carcinomas.
Journal
Reference
Authors
Tsai KY, Tsao H.
Title
The genetics of skin cancer.
Journal
Reference
Authors
Athar M, Tang X, Lee JL, Kopelovich L, Kim AL.
Title
Hedgehog signalling in skin development and cancer.
Journal
Reference
Authors
Rubin AI, Chen EH, Ratner D.
Title
Basal-cell carcinoma.
Journal
Reference
Authors
Saldanha G.
Title
The Hedgehog signalling pathway and cancer.
Journal
Reference
Authors
Saldanha G, Ghura V, Potter L, Fletcher A.
Title
Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation.
Journal
Reference
Authors
Pasca di Magliano M, Hebrok M.
Title
Hedgehog signalling in cancer formation and maintenance.
Journal
Reference
Authors
Reifenberger J, Wolter M, Knobbe CB, Kohler B, Schonicke A, Scharwachter C, Kumar K, Blaschke B, Ruzicka T, Reifenberger G.
Title
Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas.
Journal
Reference
Authors
Cohen MM Jr.
Title
The hedgehog signaling network.
Journal
Reference
Authors
Yamazaki F, Aragane Y, Kawada A, Tezuka T.
Title
Immunohistochemical detection for nuclear beta-catenin in sporadic basal cell carcinoma.
Journal
Reference
Authors
Erb P, Ji J, Wernli M, Kump E, Glaser A, Buchner SA.
Title
Role of apoptosis in basal cell and squamous cell carcinoma formation.
Journal
Reference
Authors
Toftgard R.
Title
Hedgehog signalling in cancer.
Journal
Reference
Authors
Miller AJ, Mihm MC Jr.
Title
Melanoma.
Journal
Reference
Authors
Chin L.
Title
The genetics of malignant melanoma: lessons from mouse and man.
Journal
Reference
Authors
Takata M, Saida T.
Title
Genetic alterations in melanocytic tumors.
Journal
Reference
Authors
Chudnovsky Y, Khavari PA, Adams AE.
Title
Melanoma genetics and the development of rational therapeutics.
Journal
Reference
Authors
Merlino G.
Title
Cancer biology: the weakest link?
Journal
Reference
Authors
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR.
Title
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
Journal
Reference
Authors
Levy C, Khaled M, Fisher DE.
Title
MITF: master regulator of melanocyte development and melanoma oncogene.
Journal
Reference
Authors
Tsao H, Goel V, Wu H, Yang G, Haluska FG.
Title
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
Journal
Reference
Authors
Gruss C, Herlyn M.
Title
Role of cadherins and matrixins in melanoma.
Journal
Reference
Authors
Thompson JF, Scolyer RA, Kefford RF.
Title
Cutaneous melanoma.
Journal
Reference
Authors
Omholt K, Platz A, Kanter L, Ringborg U, Hansson J.
Title
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Journal
Clin Cancer Res 9:6483-8 (2003)
Reference
Authors
Hussein MR.
Title
The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship?
Journal
Reference
Authors
Lazar-Molnar E, Hegyesi H, Toth S, Falus A.
Title
Autocrine and paracrine regulation by cytokines and growth factors in melanoma.
Journal
Reference
Authors
Cohen HT, McGovern FJ.
Title
Renal-cell carcinoma.
Journal
Reference
Authors
Pavlovich CP, Schmidt LS.
Title
Searching for the hereditary causes of renal-cell carcinoma.
Journal
Reference
Authors
Linehan WM, Walther MM, Zbar B.
Title
The genetic basis of cancer of the kidney.
Journal
Reference
Authors
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF.
Title
Met, metastasis, motility and more.
Journal
Reference
Authors
Kim WY, Kaelin WG.
Title
Role of VHL gene mutation in human cancer.
Journal
Reference
Authors
Sudarshan S, Linehan WM, Neckers L.
Title
HIF and fumarate hydratase in renal cancer.
Journal
Reference
Authors
Sudarshan S, Pinto PA, Neckers L, Linehan WM.
Title
Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.
Journal
Reference
Authors
Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG.
Title
Understanding familial and non-familial renal cell cancer.
Journal
Reference
Authors
Mitra AP, Datar RH, Cote RJ.
Title
Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.
Journal
Reference
Authors
Wolff EM, Liang G, Jones PA.
Title
Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.
Journal
Reference
Authors
Wu XR.
Title
Urothelial tumorigenesis: a tale of divergent pathways.
Journal
Reference
Authors
Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R.
Title
Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors.
Journal
Cancer Res 60:6298-302 (2000)
Reference
Authors
Bellmunt J, Hussain M, Dinney CP.
Title
Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
Journal
Reference
Authors
Sugano K, Kakizoe T.
Title
Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging.
Journal
Reference
Authors
Dunn KL, Espino PS, Drobic B, He S, Davie JR.
Title
The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling.
Journal
Reference
Authors
Williams SG, Stein JP.
Title
Molecular pathways in bladder cancer.
Journal
Reference
Authors
Nelson WG, De Marzo AM, Isaacs WB.
Title
Prostate cancer.
Journal
Reference
Authors
Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC.
Title
The emerging role of the PI3-K-Akt pathway in prostate cancer progression.
Journal
Reference
Authors
Pienta KJ, Bradley D.
Title
Mechanisms underlying the development of androgen-independent prostate cancer.
Journal
Reference
Authors
Feldman BJ, Feldman D.
Title
The development of androgen-independent prostate cancer.
Journal
Reference
Authors
Heinlein CA, Chang C.
Title
Androgen receptor in prostate cancer.
Journal
Reference
Authors
Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP.
Title
Androgen receptor gene and hormonal therapy failure of prostate cancer.
Journal
Am J Pathol 152:1-9 (1998)
Reference
Authors
Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D.
Title
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.
Journal
Reference
Authors
Macri E, Loda M.
Title
Role of p27 in prostate carcinogenesis.
Journal
Reference
Authors
Steers WD.
Title
5alpha-reductase activity in the prostate.
Journal
Reference
Authors
Lin D, Meyer DJ, Ketterer B, Lang NP, Kadlubar FF.
Title
Effects of human and rat glutathione S-transferases on the covalent DNA binding of the N-acetoxy derivatives of heterocyclic amine carcinogens in vitro: a possible mechanism of organ specificity in their carcinogenesis.
Journal
Cancer Res 54:4920-6 (1994)
Reference
Authors
Grimes CA, Jope RS.
Title
The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling.
Journal
Reference
Authors
Ryan AJ, Susil B, Jobling TW, Oehler MK.
Title
Endometrial cancer.
Journal
Reference
Authors
Lax SF.
Title
Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.
Journal
Reference
Authors
Shiozawa T, Konishi I.
Title
Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.
Journal
Reference
Authors
Hecht JL, Mutter GL.
Title
Molecular and pathologic aspects of endometrial carcinogenesis.
Journal
Reference
Authors
Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P, Prat J.
Title
Molecular pathology of endometrial hyperplasia and carcinoma.
Journal
Reference
Authors
Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH.
Title
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
Journal
Reference
Authors
Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF.
Title
Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
Journal
Cancer Res 55:5693-8 (1995)
Reference
Authors
Kim D, Chung J.
Title
Akt: versatile mediator of cell survival and beyond.
Journal
Reference
Authors
Sanchez-Cespedes M.
Title
Dissecting the genetic alterations involved in lung carcinogenesis.
Journal
Reference
Authors
Kaye FJ.
Title
Molecular biology of lung cancer.
Journal
Reference
Authors
Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF.
Title
Apoptosis and lung cancer: a review.
Journal
Reference
Authors
Sartorius UA, Krammer PH.
Title
Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines.
Journal
Reference
Authors
Adhikary S, Eilers M.
Title
Transcriptional regulation and transformation by Myc proteins.
Journal
Reference
Authors
Spruck C, Strohmaier H, Watson M, Smith AP, Ryan A, Krek TW, Reed SI.
Title
A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1.
Journal
Reference
Authors
Buttery RC, Rintoul RC, Sethi T.
Title
Small cell lung cancer: the importance of the extracellular matrix.
Journal
Reference
Authors
Yamada KM, Araki M.
Title
Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis.
Journal
J Cell Sci 114:2375-82 (2001)
Reference
Authors
Rintoul RC, Sethi T.
Title
The role of extracellular matrix in small-cell lung cancer.
Journal
Reference
Authors
Ekedahl J, Joseph B, Grigoriev MY, Muller M, Magnusson C, Lewensohn R, Zhivotovsky B.
Title
Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells.
Journal
Reference
Authors
Osada H, Takahashi T.
Title
Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer.
Journal
Reference
Authors
Yokota J, Nishioka M, Tani M, Kohno T.
Title
Genetic alterations responsible for metastatic phenotypes of lung cancer cells.
Journal
Reference
Authors
Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS.
Title
K-ras mutations in non-small-cell lung carcinoma: a review.
Journal
Reference
Authors
Pfeifer GP, Dammann R.
Title
Methylation of the tumor suppressor gene RASSF1A in human tumors.
Journal
Reference
Authors
Altucci L, Gronemeyer H.
Title
The promise of retinoids to fight against cancer.
Journal
Reference
Authors
Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF.
Title
Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas.
Journal
Reference
Authors
Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA.
Title
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.
Journal
Reference
Authors
Panani AD, Roussos C.
Title
Cytogenetic and molecular aspects of lung cancer.
Journal
Reference
Authors
Mitsuuchi Y, Testa JR.
Title
Cytogenetics and molecular genetics of lung cancer.
Journal
Reference
Authors
Breuer RH, Postmus PE, Smit EF.
Title
Molecular pathology of non-small-cell lung cancer.
Journal
Reference
Authors
Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger DC, Grizzle WE.
Title
Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung.
Journal
Clin Cancer Res 8:734-44 (2002)
Reference
Authors
Awaya H, Takeshima Y, Furonaka O, Kohno N, Inai K.
Title
Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.
Journal
Reference
Authors
Lappano R, Maggiolini M
Title
G protein-coupled receptors: novel targets for drug discovery in cancer.
Journal
Reference
Authors
O'Hayre M, Degese MS, Gutkind JS
Title
Novel insights into G protein and G protein-coupled receptor signaling in cancer.
Journal
Reference
Authors
Dorsam RT, Gutkind JS
Title
G-protein-coupled receptors and cancer.
Journal
Related pathway
hsa04060 Cytokine-cytokine receptor interaction
KO pathway